Clinical Trial

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Study acronym: TUXEDO-2
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2025 (before its estimated May 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-10; most recent amendment 2025-09-22.
Status change: Not Yet Recruiting → Recruiting 2023-05-19
Trial Details
NCT Number NCT05866432
Lead Sponsor Medical University of Vienna
Collaborators: Daiichi Sankyo
Conditions Breast Cancer Stage IV
Enrollment 20 participants
Start Date 2023-07-01
Primary Completion 2026-05-23 (estimated)
Study Completion 2026-05-23 (estimated)
Updated on ClinicalTrials.gov 2025-09-25